Humanetics Corporation
Colin Chinn serves as Chief Medical Officer at Humanetics Corporation since March 2020, also holding the role of Medical Advisor. Previously, Colin Chinn was Chief Medical Officer at Peraton from March 2021 to September 2023, and Consulting Medical Officer at Northrop Grumman from February 2020 to March 2021. Additional experience includes serving as Scholar-in-Residence at Uniformed Services University of the Health Sciences and Joint Staff Surgeon for the Office of the Chairman of the Joint Chiefs of Staff. Colin Chinn held the position of Director of J9 Research and Development at the Defense Health Agency, overseeing a $2.2 billion Defense Health Program RDT&E appropriation. Prior positions also include Command Surgeon at US Pacific Command, Director at Medical Resources, Plans and Policy for the Chief of Naval Operations, and Director (CEO) of TRICARE Region-West/Pacific. Educational background includes a Doctor of Medicine degree from the Medical College of Virginia, a Master of Health Science in Epidemiology from The Johns Hopkins University, and a Bachelor of Arts in Public Health from The Johns Hopkins University.
This person is not in any teams
Humanetics Corporation
Humanetics is a privately held, clinical stage pharmaceutical company located in the Minneapolis metropolitan area. Our lead candidate, BIO 300 is being developed for multiple clinical uses with a primary focus on improving treatment of solid tumor cancers. BIO 300 is being developed as an agent to both sensitize tumor cells to enhance radiation treatment efficacy and to protect normal tissues from harm. Thus, reducing common treatment related side effects such as radiation induced pneumonitis, erectile dysfunction, mucositis and xerostomia. BIO 300 is also under development for inflammatory lung diseases with an immediate focus on mitigation of pulmonary injury due to COVID-19. A recent contract from NIAID will fund a phase 2 study on BIO 300 in recovering COVID patients in an effort to stem progressive long-term lung complications, such as fibrosis. BIO 300 was licensed from the US Department of Defense, where it was originally developed to prevent injuries associated with ionizing radiation. This program is still underway with a focus on prevention of acute radiation syndrome as well as lung injury. For more information about Humanetics, please visit our corporate website at www.humaneticscorp.com.